San Diego-based company, Evofem, hoping to change contraceptive market
Amphora in global clinical trials
Last Updated: 136 days ago
San Diego - A San Diego-based bio-tech firm, Evofem, is hoping to change the contraceptive market across the world with product called Amphora.
The company's president talked to 10News for our "Staying Healthy" segment.
According to their website, Evofem LLC is a privately held bio-technology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, the firm discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception and the prevention of sexually transmitted infections.
Amphora is described as a non-hormonal vaginal contraceptive gel, currently undergoing a global Phase III clinical trial to prove its efficacy. Amphora is already FDA-approved as a sexual lubricant and is anticipated to fill a critical gap in the market as an inexpensive, easy-to-use product that is woman-controlled and only used when necessary, on-demand.
President of Evofem and lifelong San Diegan, Sean Edwards, said Amphora is a woman-controlled, non-hormonal, pericoital choice of birth control for women.
"It gives women added choice and added options," said Edwards. "The fact that it's pericoital means they use it only when they need it. They don't have to use it everyday, they don't have to forget to take a pill and the fact that it's woman controlled means they don't have to see a doctor to use the product."
Evofem hopes to have the product available over the counter in the U.S. and to get the product to women in developing countries.
"So a global game changer, in our opinion, in a product that is woman controlled and the fact that a woman can use it when she needs it, not have to use it everyday is so significant in the markets where we work," said WomanCare Global CEO Saundra Pelletier.
Evofem has partnered with the non-profit to get Amphora to the women who don't have access to birth control.
"Sometimes these women will walk two days, they are pregnant, they have a baby on their back, they have a baby on their side and sometimes they get a pack of sugar pills and sometimes they get up to the door and there is no more available," said Pelletier.
According to the company, through various studies, Amphora has shown potential to be effective in protecting against sexually transmitted infections (STIs) including HIV, but more tests are needed.
Also download our 10News mobile and tablet apps to stay up-to-date with developing stories when you are on the go: http://www.10news.com/about/mobile.
Copyright 2013 Scripps Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.